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Abstract: Cartilage is an avascular tissue and cartilage metabolism depends on molecule 
diffusion from synovial fluid and subchondral bone. Thus, nutrient availability is limited 
by matrix permeability according to the size and charge of the molecules. Matrix 
composition limits the access of molecules to chondrocytes, determining cell metabolism 
and cartilage maintenance. Lipids are important nutrients in chondrocyte metabolism and 
are available for these cells through de novo synthesis but also through diffusion from 
surrounding tissues. Cartilage status and osteoarthritis development depend on lipid 
availability. This paper reviews lipid transport and metabolism in cartilage. We also 
analyze signalling pathways directly mediated by lipids and those that involve mTOR 
pathways, both in normal and osteoarthritic cartilage. 
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1. Introduction 
Lipid content in cartilage has been studied for many years. In the 1960s, Stockwell found that lipids 
in articular cartilage account for 1%, although this content was not modulated by age or sex [1]. While 
glucose is the main source of energy in chondrocytes [2], lipids in cartilage are necessary for cells as a 
source of energy but also to be incorporated as structural components and signalling molecules. 
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Cholesterol and fatty acids are the lipids that have been most frequently linked to cartilage 
physiopathology [3]. However, less is known about how these molecules can reach the chondrocytes 
and, once there, how lipids affect chondrocyte metabolism. 
Proteins necessary for fatty acid metabolism and cholesterol biosynthesis, such as acetyl-coenzyme 
A acetyltransferase 1 (ACAT1), cytochrome P450 oxidase, family 51, sub-family A, polypeptide 1 
(CYP51A1), 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS) or low density lipoprotein 
receptor (LDLR), have been detected in human chondrocytes [4]. In addition, lipids in joint fluid can 
also penetrate into cartilage [5]. Therefore, lipids may be available for chondrocytes directly from 
synovial fluid or by de novo synthesis. 
Nevertheless, cartilage is an avascular tissue, so lipids need to travel through its compact matrix 
reaching the cells, which represent only about 2%–5% of total tissue, for supplying the chondrocyte 
metabolism. Therefore to better understand the role of lipids in chondrocyte metabolism it is necessary 
to analyze how these molecules are supplied to chondrocytes and afterwards to study lipid effects on 
cell metabolism. 
2. Transporting Lipids through the Cartilage 
Articular cartilage matrix is composed of 10%–30% collagen and 3%–10% proteoglycans and other 
minor glycoproteins and lipids. Proteoglycans, with a high anionic charge, provide the matrix with 
osmotic properties that allow cartilage resistance to loading, while also interacting with collagen to 
establish a network [6,7]. Therefore, cartilage matrix is basically a high negative charged network with 
large swelling pressure and tensile stress, where water and dissolved electrolytes filling the pores 
account for between 60% and 85% of total weight [7]. This complex structure determines the ability of 
articular cartilage to resist compressive loads, but also determines how molecules penetrate this matrix. 
Small neutral solutes can diffuse freely from joint fluid into cartilage, while ionic and larger 
molecules show altered movement through the matrix. As described above, cartilage matrix is 
negatively charged which means that small anionic molecules are partially excluded, and the opposite 
occurs with small cationic solutes. Moreover, the ability to penetrate the cartilage matrix depends on 
the valency, which determines molecule affinity for the matrix [8]. 
Proteoglycans are heterogeneously distributed throughout the matrix [9], and variations in tissue 
fixed charge density may influence solute diffusion, mostly for larger molecules [8]. The main role of 
proteoglycans in molecule diffusion was corroborated by digesting human articular cartilage with 
several proteases, although this process did not affect the circulation of small solutes. However, 
although collagen removal did not alter the diffusive properties of any molecule, cathepsin D and 
trypsin digestions increased the diffusion of large molecules [10]. 
Lipids are usually found in blood as lipoproteins or bound to carrier plasma proteins in order to 
increase their solubility. This way, lipids become part of a large complex which restricts their transport 
through cartilage since size is a determining factor for molecule diffusion [11]. However, as  
Arkill et al. [11] suggested, this is not always the case, since lauric acid dissociates from albumin in 
cartilage surface and independently diffuses into the cartilage. In fact, this fatty acid was detected in 
the entire cartilage, accumulating in the tidemark [11]. 
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Despite a different matrix composition, mature and immature cartilage show similar permeability, 
at least for uncharged solutes [12]. However, mature joints present a calcified cartilage in the  
bone-cartilage interface that does not exist in immature joints. This natural barrier could strongly 
interfere with the diffusion of lipids and other nutrients from calcified to non-calcified cartilage. 
Taking into account that diffusion of large molecules through cartilage matrix may be restricted, it is 
very important to understand what the possible nutrient sources in the joint are. Several studies have 
been carried out considering two alternatives: diffusion from synovial fluid and interchange from 
subchondral bone (SB). 
There are big controversies about the SB as a source providing nutrients such as lipids to the 
cartilage, with the calcified cartilage in the bone-cartilage interface of mature joints being an important 
point in this debate. No nutrient diffusion from SB has been found in mature rabbits [13–15]; however, 
transport of molecules from SB has been shown in horses and mice [16,17]. In fact, mice present  
non-mineralized regions in calcified cartilage, forming pores to allow solute transport between 
cartilage and SB in mature joints [16]. 
Regarding human cartilage, it was firstly suggested that vascular channels penetrating from SB 
allowed molecule diffusion through calcified cartilage in human mature joints [18]. More recently the 
chondro–osseous junction in mature human cartilage was described as a complex 3D structure which 
presents a clearly defined tidemark that follows uncalcified cartilage prolongations crossing calcified 
cartilage to contact with bone and bone marrow vessels, allowing molecular trafficking [19]. 
Unlike subchondral bone, synovial fluid is widely accepted as a main source of molecules for 
articular cartilage metabolism [20,21]. In fact, Wang et al. [20] found that synovial fluid, but not SB, 
provides enough nutrients to maintain cartilage structure and function in mature rabbits. 
In this regard, it is noteworthy that joints are subjected to compression and cyclic loading in vivo, 
modifying molecule diffusion from synovial fluid. Although molecule diffusion occurs in the absence 
of mobilization, fluid stirring and convection and cyclic loading are important for the diffusion of 
small solutes but even more for large solutes [22–24]. 
2.1. Osteoarthritis and Lipid Availability 
Osteoarthritis (OA) is characterized by high levels of proteases that degrade cartilage matrix [25]. 
As stated above, this process involves increased cartilage permeability, which in turn could contribute 
to OA evolution [10]. Matrix components synthesized by chondrocytes in an attempt to repair  
the damaged cartilage could be lost in the joint space, being an unproductive effort [10].  
Moreover, deleterious agents such as toxins and immunoglobulins, usually excluded from the 
cartilage, could reach chondrocytes and induce metabolic changes [10]. In fact, OA synovial fluid 
presents high levels of plasma proteins, which could easily reach chondrocytes and induce 
proinflammatory responses [26] (Table 1). 
Moreover, OA cartilage does not only receive high levels of molecules from synovial fluid due to 
an increase in an aberrant permeability. Pan et al. found that during OA the cross-talk between SB and 
articular cartilage is enhanced due to an increase in the number of vessels invading the calcified 
cartilage [27]. In turn, immobilization and disability due to pain in OA patients may also affect 
cartilage permeability and therefore nutrient availability for the chondrocytes [22] (Table 1). 
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Table 1. Altered cartilage permeability during osteoarthritis (OA). 
Altered cartilage permeability Events related to OA References
Causes 
Increased protease activity [25] 
Increased subchondral vessels invading calcified cartilage [27] 
Joint immobilization [22] 
Consequences 
Loss of matrix components in the joint space [10] 
Access of deleterious agents (toxins, immunoglobulins) [10] 
Access of proinflammatory plasma proteins [26] 
3. Lipids in Normal Cartilage 
As stated above, human chondrocytes express several proteins for fatty acid metabolism and 
cholesterol biosynthesis. These molecules are up-regulated during chondrogenesis, indicating a high 
cholesterol biosynthesis in these cells [4]. In fact, cholesterol biosynthesis is required for expression of 
Ihh in rat chondrocytes and for normal growth plate chondrogenesis in rats [28,29]. 
On the other hand, leptin-like oxidized LDL (oxLDL) receptor 1 (LOX-1) [30] and Liver X receptor 
(LXR) [31] have been detected in human cartilage. These data indicate that chondrocytes are indeed 
able to modulate lipid homeostasis in the cartilage by sensing and transporting lipoproteins from the 
extracellular matrix. 
Synovial fluid is an ultrafiltrate of plasma. However, plasma lipids are transported in large 
complexes so that human synovial fluid presents very low concentrations of lipoproteins in contrast  
to plasma [32,33]. It is important to note that the inflammation and vascular permeability of synovium 
determine the levels of lipoproteins in synovial fluid. Thereby, the ratio of synovial fluid to plasma of 
ApoA1, ApoB and Lp(a) is about 1.5 times higher in inflammatory arthritides like rheumatoid and 
psoriatic arthritis than in OA [33]. 
Despite being able to penetrate into cartilage, lipid content constitutes less than 1% of the total 
tissue weight [1]. High cholesterol content is found in chondrocyte cell membrane [34], indicating the 
importance of this lipid for structural maintenance in chondrocytes. In addition, the phytosterol 
stigmasterol is able to integrate in the chondrocyte membrane during culture [35]. On the other hand, 
palmitic, oleic and linoleic acids (16:0, 18:1n-9 and 18:2n-6) account for almost 85% of total fatty acid 
content in cartilage [36]. Moreover, their presence in cartilage is subjected to age-related changes. 
Studies both in humans and sheep demonstrated that fetal cartilage differs in lipid composition from 
mature cartilage. Indeed, human mature cartilage showed decreased monounsaturated and ω-3 fatty 
acids, while saturated fatty acids were increased [37]. In addition, arachidonic acid (20:4n-6) is higher 
in fetal cartilage meanwhile linoleic acid (18:2n-6) increases in mature cartilage (Table 2) [37]. 
Moreover, cultured growth plate chondrocytes present higher content in lipids than cultured  
articular chondrocytes [38]. 
It is noteworthy that, besides physiological modification of lipid content, the fatty acid composition 
in cartilage may be modulated by dietary lipids intake [39,40]. Diets containing high levels of ω-3  
fatty acids lead to a decrease in arachidonic (20:4n-6) and linoleic acids (18:2n-6) and an increase  
in eicosapentaenoic acid (20:5n-3) in cartilage [39,40]. In addition, Nagao et al. demonstrated that 
extracellular fatty acids modulate intracellular lipid composition in cultured chondrocytes [41]. 
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Table 2. Fatty acid composition in normal cartilage. 
Cartilage maturation stage Cartilage composition References 
Mature cartilage 
↑ saturated fatty acids [37] 
↑ linoleic acid [37] 
Fetal cartilage 
↑ ω-3 fatty acids [37] 
↑ mono-unsaturated fatty acids [37] 
↑ arachidonic acid [37] 
As stated above, cholesterol plays an important role as a structural molecule. However, the main 
effect of fatty acids in cartilage is through its conversion to eicosanoids. Both ω-3 and ω-6 fatty acids 
are substrates for cyclooxygenase and lipoxygenase enzymes, which synthesize prostaglandins and 
leukotrienes. These products derived from ω-3 fatty acids show anti-inflammatory properties, while 
those derived from ω-6 are pro-inflammatory and pro-thrombotic [42]; in fact, inhibition of 
cyclooxygenase results in less inflammatory mediators [43,44]. However, ω-6 fatty acids are also 
important for membrane structure and function, so it is necessary to maintain an appropriate ratio of  
ω-6 to ω-3, with 4:1 to 1:1 recommended [45]. 
Phospholipids are also important for normal cartilage maintenance. Besides being cell membrane 
constituents, phospholipids are key molecules in synovial fluid, playing a main role in joint  
lubrication to protect cartilage surfaces. In fact, phosphatidylethanolamine, phosphatidylcholine and 
sphingomyelin are major components of the articular cartilage boundary lubricant [46]. In addition to 
the presence of these phospholipids in the joint fluid, free fatty acids may be incorporated by 
chondrocytes into phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI) 
and triacylglycerol (TG) [41,47]. 
Therefore, lipids are essential for cartilage physiology, and modifications in their availability and 
metabolism may have pathological consequences. 
4. Lipids in Osteoathritic Cartilage 
In recent years, OA has been linked to metabolic syndrome, which is characterized by  
dyslipidemia [48]. In fact, several studies have found an association between hypercholesterolemia  
and OA [49–51]. Therefore, some epidemiological studies have tried to elucidate the possible 
relationship between statin treatment to reduce serum cholesterol levels and OA development. 
However, the interpretation of the results of these studies presents some limitations regarding the 
evaluation of OA progression [52], leading to different conclusions. Clockaerts et al. [53] and  
Kadam et al. [54] found a reduced progression of knee OA in statin users; on the contrary, Riddle et al. [55] 
did not find an improvement in knee pain, function or structural progression, while Beattie et al. [56] 
concluded that statins did not influence the progression of an established OA. 
Despite these controversies, the potential of statins to reduce OA has been observed in vitro and in 
animal models. In fact, statin treatment reduced OA progression in rats [57] and mice [58], and 
decreased pro-inflammatory and catabolic mediators in cultured chondrocytes [59–61]. However, 
cholesterol biosynthesis plays an important role in chondrogenesis [28,29]. Accordingly, these 
beneficial effects of statins have been related to reduced protein geranylgeranylation rather than 
inhibition of cholesterol synthesis itself [60,62]. 
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Several studies have shown the beneficial effects of ω-3 fatty acids in inflammatory diseases such 
as rheumatoid arthritis (RA), recommending their use as part of the normal diet of patients [42]. 
However, only a few studies, without conclusive results, have been carried out in OA. Treating OA 
patients with cod liver oil, which contains high levels of eicosapentanoic acid (20:5n-3), in addition to 
non-steroidal anti-inflammatory drugs (NSAIDs) for 24 weeks showed no benefits versus olive oil [63]. 
However, the anti-inflammatory properties of several olive oil components could have attenuated the 
differences due to fatty acid composition [64]. In keeping with the lack of cod liver oil effect,  
Wang et al. found a correlation between ω-6 fatty acids intake and development of bone marrow 
lesions, but not with cartilage volume or damage [65]. In contrast, a recent study showed that total ω-3 
fatty acids and the specific docosahexanoic acid (22:6n-3) were inversely correlated with 
patellofemoral cartilage loss, while ω-6 fatty acids showed no association [66]. Moreover, an animal 
model of spontaneous OA fed with a ω-3 fatty acids-enriched diet showed a lower pathology score, 
with increased glycosaminoglycan content, reduced denatured type II collagen, and reduced MMP-2 
activity [67]. Very recently, Huang et al. found that decreasing ω-6 to ω-3 ratio by endogenous 
conversion of ω-6 to ω-3 fatty acids in mice delayed OA development [68]. Therefore, a beneficial 
effect of ω-3 fatty acids for OA cartilage may exist, although further in vivo and in vitro studies are 
needed to demonstrate it. 
As stated above, phospholipids are important in joint lubrication. However, most of the 
phospholipids present in synovial fluid appear increased in OA, which could assist OA pathogenesis in 
modulating inflammatory responses [69]. In addition, high levels of phospholipase A2 are present in 
OA synovial fluid [70], where the main sources of this enzyme are the chondrocytes [71]. In fact, 
cytokines present in OA joints such as IL-1 are able to activate phospholipase A2 in chondrocytes, 
suggesting that this enzyme may play a role in the OA development [72]. Moreover, the activity of 
phospholipase A2 in OA synovial fluid could contribute to a release of fatty acids, which penetrate the 
cartilage matrix more easily than large complexes [11]. 
As with synovial fluid, lipid accumulation has been described in articular cartilage during OA 
development, despite the fact that diet association in OA still needs clarification. In fact, using imaging 
mass spectrometry, Cillero-Pastor et al. [34] have recently shown that cholesterol and fatty acids 
specifically accumulate in the superficial area of OA cartilage. Moreover, reduced expression of  
LXR and ApoA1 has been described in human OA cartilage, leading to impaired cholesterol efflux  
and finally intracellular lipid deposits in OA chondrocytes [31]. In fact, ApoA1−/− mice  
spontaneously developed OA when fed a western-type diet due to alterations in HDL metabolism [73].  
Changes in cartilage lipid composition are correlated with disease severity, with increases in total  
fatty acid of 440% in the advanced stages of OA [36]. Lippiello et al. suggested that high levels of 
arachidonic acid (20:4n-6) in OA could be related to the elevated eicosanoid synthesis usually found in 
this disease [36]. Therefore, altered lipid metabolism could be a risk factor and/or consequence  
of OA [34]. 
Lipid deposition in cartilage during OA has more consequences than merely accumulation itself. 
OA is characterized by an increase in reactive oxygen species, which are responsible for lipid 
peroxidation [74]; thus, lipid peroxidation products are usually found in joints from these  
patients [75,76]. Several studies have reported that these molecules contribute to cartilage degradation 
and OA pathogenesis, since they induce collagen oxidation and cleavage and MMP-13  
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activity [74,76]. Thereby, antioxidant treatment may be useful for OA not only by reducing reactive 
oxygen species [77] but also lipid peroxidation. 
5. Lipids and Chondrocyte Metabolism 
Besides its structural role, cholesterol is also an important signal in chondrocyte biology. LXR is a 
sensor of oxygenated cholesterol derivatives, which activates transcription of important genes to 
protect cells from cholesterol overload. This receptor is modulated during chondrocyte differentiation 
and regulates cholesterol homeostasis during this process [78]. In fact, cholesterol signalling stimulates 
in vitro chondrocyte hypertrophy through nuclear receptor retinoid related orphan receptor-α (Ror-α) 
expression [79], and it is also necessary for apoptosis protection and Ihh expression during 
chondrogenesis and growth plate development [28,29] (Figure 1). 
Figure 1. Summary of lipid actions in cartilage metabolism and response to stress. Green 
arrows indicate activation and red arrows inhibition of the processes shown in the squares. 
References are indicated in brackets. 
 
As stated above, OA chondrocytes express LOX-1, a scavenger receptor for oxLDL. oxLDL has 
been detected in human OA and RA cartilage [80,81], and stimulates senescence in human 
chondrocytes in vitro [82] by decreasing cell viability [30,81]. Moreover, this molecule induces 
reactive oxygen species production and hypertrophic-like changes in bovine chondrocytes [83,84], 
reduces proteoglycan synthesis in human chondrocytes [81] and increases MMP-3 production in 
human cartilage explants [80] and MCP-1 expression in human chondrocytes [85] (Figure 1). 
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The effects of fatty acids on chondrocyte metabolism support the potential benefits of adequate 
lipid content in diet. During in vitro experiments, bovine chondrocytes rapidly incorporated both 
arachidonic acid (20:4n-6) and oleic acid (18:1n-9). However, only arachidonic acid elicited metabolic 
changes, with increased matrix and prostaglandin synthesis [86]. Moreover, unlike arachidonic (20:4n-6), 
linoleic (18:2n-6), oleic (18;1n-9) and palmitic (16:0) acids, ω-3 fatty acids decrease proteinases 
involved in cartilage matrix degradation, COX-2, IL-1α, IL-1β and TNFα expression in  
chondrocytes [87,88] (Figure 1). However, rats fed 10% menhaden oil, which contains high levels of 
ω-3 fatty acids, showed a decrease in linoleic (18:2n-6) and arachidonic (20:4n-6) acids together with 
low proteoglycan synthesis and irregularities in cartilage [39]. This study points to the importance of  
an appropriate ω-6 to ω-3 ratio, where a high ratio may be as harmful as a very low one. 
Ceramide is another lipid that is increased in the synovial fluid of OA patients [69]. Ceramide 
might play a mediatory role in cartilage loss during OA due to increased chondrocyte apoptosis and  
by inducing proteoglycan degradation [89]. High levels of endogenous ceramide have been  
demonstrated to disrupt cartilage matrix homeostasis, resulting in down-regulation of type II collagen 
in articular cartilage [90,91]. In fact, acid ceramidase, by degrading ceramide, alters sphingolipid 
metabolism and improves chondrogenesis [92] (Figure 1). 
The mammalian target of rapamycin (mTOR) signalling pathway integrates both intracellular  
and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation  
and survival. Nutrients and energy status modulate mTOR signalling, leading to modifications in 
protein and lipid synthesis, lipid and glucose metabolism and autophagy [93]. Although mTOR is a 
critical regulator of lipid biosynthesis, its role as a lipid-sensing molecule has been studied to a  
lesser extent [94]. Palmitic acid (16:0) induces insulin resistance through activation of mTOR in 
skeletal muscle cells and hepatocytes [95,96], and a high-fat diet also induced insulin resistance in 
skeletal muscle in rats by mTOR activation [96]. In addition, arachidonic acid (20:4n-6) activates 
amino acid-independent mTOR signalling in breast cancer cells, inducing proliferation and 
angiogenesis [97]; however, ceramide induces autophagy by inhibiting mTOR signalling in several 
cell types [98]. mTOR has also been implied in macrophages’ intracellular cholesterol homeostasis, 
regulating the expression of important genes for cholesterol metabolism such as ABCA1, LOX-1 and 
LXR [99]. In addition, cholesterol membrane content is a regulator of mTOR signalling in endothelial 
cells, since alteration in cholesterol distribution in plasma membrane blunts mTOR pathway [100]. 
Therefore, mTOR is related to lipid-induced responses in different cell types. This pathway can 
induce insulin resistance and modulate cell proliferation and angiogenesis in response to specific fatty 
acids, and membrane cholesterol also seems to be necessary for mTOR signalling. However, little is 
known about this signalling pathway in chondrocytes. It has been implicated in the process of 
chondrocyte differentiation, through modulation of autophagy and Ihh expression [101,102]. In fact, 
inhibition of mTOR by rapamycin prevents chondrocyte differentiation, showing an important role for 
mTOR in this process [79]. Autophagy has been proposed as a protective mechanism in normal 
cartilage; this way, aging and OA-related autophagy loss could be involved in cartilage damage during 
these situations [103]. Accordingly, autophagy induction by mTOR blockade using rapamycin in  
OA mice reduced disease severity, as shown by less cartilage degradation [104]. In contrast,  
Sasaki et al. found increased autophagy in OA chondrocytes, however, they also suggested that 
rapamycin-induced autophagy is a protective mechanism from stresses [105]. According to results in 
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other cell types, arachidonic acid (20:4n-6) has been described as an activator of mTOR signalling in 
mice chondrocytes, while docosahexaenoic acid (22:6n-3) reverts this effect [68]. This recent study 
further confirms the beneficial role of ω-3 fatty acids in chondrocytes, inhibiting mTOR and activating 
autophagy as a protective mechanism for cartilage maintenance [68]. 
6. Conclusions 
Lipids such as phospholipids, cholesterol and fatty acids are present in articular cartilage and 
synovial fluid. Chondrocytes can synthesize these molecules, however, dietary lipids may also reach 
the cartilage, modify its composition and be incorporated in chondrocyte metabolism and structures.  
In fact, impaired cholesterol efflux and intracellular lipid deposits, as well as fatty acid accumulation 
in cartilage, have been related to OA development. 
Several studies have suggested that anti-inflammatory and anti-catabolic properties of ω-3 fatty acids, 
as well as their capacity to inhibit mTOR signalling and promote autophagy, may be used to treat  
OA symptoms and progression. Therefore, an appropriate lipid intake could contribute to improving 
lipid balance in cartilage, preventing chondrocyte metabolism alterations and cartilage damage. 
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